$0.13 EPS Expected for Vanda Pharmaceuticals Inc. (VNDA) This Quarter

Brokerages expect Vanda Pharmaceuticals Inc. (NASDAQ:VNDA) to announce earnings per share of $0.13 for the current fiscal quarter, Zacks Investment Research reports. Three analysts have made estimates for Vanda Pharmaceuticals’ earnings, with the highest EPS estimate coming in at $0.14 and the lowest estimate coming in at $0.12. Vanda Pharmaceuticals reported earnings of ($0.04) per share in the same quarter last year, which would suggest a positive year over year growth rate of 425%. The company is scheduled to issue its next earnings report on Wednesday, February 13th.

On average, analysts expect that Vanda Pharmaceuticals will report full-year earnings of $0.51 per share for the current fiscal year, with EPS estimates ranging from $0.31 to $0.62. For the next fiscal year, analysts anticipate that the business will post earnings of $0.60 per share, with EPS estimates ranging from $0.20 to $0.92. Zacks Investment Research’s EPS averages are an average based on a survey of sell-side research analysts that that provide coverage for Vanda Pharmaceuticals.

Vanda Pharmaceuticals (NASDAQ:VNDA) last announced its earnings results on Wednesday, November 7th. The biopharmaceutical company reported $0.13 EPS for the quarter, beating the Zacks’ consensus estimate of ($0.05) by $0.18. Vanda Pharmaceuticals had a net margin of 7.06% and a return on equity of 5.88%. The firm had revenue of $49.13 million for the quarter, compared to analysts’ expectations of $49.44 million. During the same quarter in the previous year, the business posted ($0.03) EPS. The company’s quarterly revenue was up 18.9% on a year-over-year basis.

VNDA has been the topic of a number of research reports. TheStreet upgraded shares of Vanda Pharmaceuticals from a “c” rating to a “b-” rating in a report on Friday, October 26th. Zacks Investment Research upgraded shares of Vanda Pharmaceuticals from a “hold” rating to a “buy” rating and set a $23.00 target price on the stock in a report on Tuesday, November 6th. BidaskClub cut shares of Vanda Pharmaceuticals from a “strong-buy” rating to a “buy” rating in a report on Thursday, November 1st. Stifel Nicolaus restated a “buy” rating on shares of Vanda Pharmaceuticals in a report on Wednesday, October 31st. Finally, Oppenheimer set a $29.00 target price on shares of Vanda Pharmaceuticals and gave the company a “buy” rating in a report on Wednesday, October 3rd. Three research analysts have rated the stock with a hold rating, six have issued a buy rating and three have assigned a strong buy rating to the company. The stock presently has an average rating of “Buy” and an average target price of $38.38.

In other news, CFO James Patrick Kelly sold 6,061 shares of Vanda Pharmaceuticals stock in a transaction dated Thursday, January 3rd. The stock was sold at an average price of $26.37, for a total value of $159,828.57. Following the completion of the transaction, the chief financial officer now owns 196,221 shares of the company’s stock, valued at approximately $5,174,347.77. The transaction was disclosed in a legal filing with the SEC, which is available through the SEC website. Also, SVP Gian Piero Reverberi sold 1,130 shares of Vanda Pharmaceuticals stock in a transaction dated Wednesday, January 2nd. The stock was sold at an average price of $26.59, for a total value of $30,046.70. Following the completion of the transaction, the senior vice president now directly owns 136,569 shares of the company’s stock, valued at approximately $3,631,369.71. The disclosure for this sale can be found here. In the last ninety days, insiders sold 22,427 shares of company stock valued at $591,496. 7.80% of the stock is owned by insiders.

Several institutional investors and hedge funds have recently bought and sold shares of VNDA. Bank of New York Mellon Corp raised its position in shares of Vanda Pharmaceuticals by 4.8% in the 2nd quarter. Bank of New York Mellon Corp now owns 214,370 shares of the biopharmaceutical company’s stock worth $4,084,000 after purchasing an additional 9,796 shares during the last quarter. Schwab Charles Investment Management Inc. raised its position in Vanda Pharmaceuticals by 2.6% in the 2nd quarter. Schwab Charles Investment Management Inc. now owns 391,939 shares of the biopharmaceutical company’s stock worth $7,467,000 after buying an additional 9,802 shares during the last quarter. BlackRock Inc. raised its position in Vanda Pharmaceuticals by 16.3% in the 2nd quarter. BlackRock Inc. now owns 4,960,924 shares of the biopharmaceutical company’s stock worth $94,506,000 after buying an additional 693,922 shares during the last quarter. Renaissance Technologies LLC raised its position in Vanda Pharmaceuticals by 2.5% in the 2nd quarter. Renaissance Technologies LLC now owns 1,681,250 shares of the biopharmaceutical company’s stock worth $32,028,000 after buying an additional 41,200 shares during the last quarter. Finally, Bank of America Corp DE raised its position in Vanda Pharmaceuticals by 3.3% in the 2nd quarter. Bank of America Corp DE now owns 189,936 shares of the biopharmaceutical company’s stock worth $3,619,000 after buying an additional 6,040 shares during the last quarter. 99.33% of the stock is owned by hedge funds and other institutional investors.

Shares of VNDA stock traded down $1.02 during mid-day trading on Thursday, reaching $30.03. 618,295 shares of the company’s stock traded hands, compared to its average volume of 624,242. Vanda Pharmaceuticals has a 12 month low of $13.88 and a 12 month high of $33.44. The stock has a market cap of $1.63 billion, a PE ratio of -85.80, a price-to-earnings-growth ratio of 0.91 and a beta of 0.69.

About Vanda Pharmaceuticals

Vanda Pharmaceuticals Inc, a biopharmaceutical company, focuses on the development and commercialization of products for the treatment of central nervous system disorders. The company's marketed products include HETLIOZ (tasimelteon), a product for the treatment of non-24-hour sleep-wake disorders; and Fanapt (iloperidone), a product for the treatment of schizophrenia.

Recommended Story: Terms to Better Understand Call Options

Get a free copy of the Zacks research report on Vanda Pharmaceuticals (VNDA)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Vanda Pharmaceuticals (NASDAQ:VNDA)

Receive News & Ratings for Vanda Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Vanda Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply